MedTrace Logo

Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma

NCT05021770 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2021-08-26

No results posted yet for this study

Summary

The purpose of this study was to investigate the maximum tolerated dose and efficacy of Orelabrutinib combined with Thiotepa in refractory and relapsed primary central nervous system lymphoma (PCNSL).

Conditions

  • Refractory and Relapsed Primary CNS Lymphoma
  • PCNSL
  • Non Hodgkin Lymphoma

Interventions

DRUG

Orelabrutinib

150mg or 200mg orally daily

DRUG

Orelabrutinib

RP2D

DRUG

Thiotepa

30 mg/m2 intravenously every 3 weeks (maximum 6 cycle)

Sponsors & Collaborators

  • Guangdong 999 Brain Hospital

    collaborator OTHER

  • Huiqiang Huang

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-31
Primary Completion
2022-12-31
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05021770 on ClinicalTrials.gov